Scope
NICE NG35 provides a baseline framework for myeloma investigation, supportive management, transplant assessment and monitoring. Its drug recommendations are linked to technology appraisals; this summary focuses on diagnostic and complication-management decisions rather than presenting the older guideline as a complete current treatment sequence.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm the paraprotein and characterize marrow disease
- Use serum protein electrophoresis with serum-free light chains to identify a paraprotein suggesting myeloma or MGUS; if electrophoresis is abnormal, use serum immunofixation to confirm it. None of these tests, or urine electrophoresis, excludes myeloma when used alone. [1]
- For marrow confirmation, use morphology for plasma-cell percentage and flow cytometry for phenotype. Use the same marrow sample for diagnostic and prognostic testing to avoid another aspirate and trephine. [1]
- Perform FISH on CD138-selected plasma cells for t(4;14), t(14;16), 1q gain, del(1p) and del(17p)/TP53 deletion, and interpret these with the International Staging System. Use serum-free light-chain measurements and their ratio for additional prognosis. [1]
Choose whole-body imaging appropriately
- Offer imaging when a plasma-cell disorder is suspected to be myeloma. Consider whole-body MRI first, then low-dose whole-body CT if MRI is unsuitable or declined; use a skeletal survey only when both are unsuitable or declined. [1]
- Do not use isotope bone scanning to identify myeloma bone disease. In newly diagnosed or smouldering myeloma without prior appropriate whole-body imaging, consider MRI, CT or FDG PET-CT to assess bone disease and extramedullary plasmacytomas. [1]
- For non-secretory disease or suspected or confirmed soft-tissue plasmacytomas, consider baseline whole-body MRI or FDG PET-CT if neither has already been performed. [1]
Assess treatment fitness and respond to acute renal disease
- Assess first autologous transplant suitability using frailty and performance measures that include comorbidity. Do not exclude suitability on age or renal impairment alone. [1]
- Allogeneic transplantation is suitable for only a small group. Assess disease sensitivity, previous treatment, donor match, complications and transplant mortality against potential long-term benefit and newer alternatives; consider a trial when available. [1]
- For untreated, newly diagnosed myeloma causing acute renal disease, consider immediate bortezomib–dexamethasone-based combination treatment. If unsuitable, the guideline gives a thalidomide–dexamethasone-based alternative; it states not to use plasma exchange for this indication. [1]
Prevent skeletal complications and manage instability
- Offer zoledronic acid to prevent bone disease, or disodium pamidronate if it is contraindicated or not tolerated; sodium clodronate is an alternative when both are unsuitable. Arrange dental assessment before IV bisphosphonates where possible, or promptly after urgent treatment starts. [1]
- Assess non-spinal fracture risk. Consider surgical stabilization followed by radiotherapy for fractured or high-risk bones, or radiotherapy alone when surgery is unsuitable or not immediately needed. [1]
- For spinal bone disease, provide bisphosphonates and systemic pain control as appropriate, and consider bracing or interventional pain management. With radiological instability, consider immediate spinal surgery or cement augmentation, each with or without radiotherapy; consider radiotherapy alone only if spinal intervention is unsuitable or not currently needed. [1]
Prevent infection and respond to treatment toxicity
- Offer seasonal influenza vaccination and consider pneumococcal vaccination for those under 65. Consider immunoglobulin replacement when hypogammaglobulinaemia and recurrent infections are both present, and test for hepatitis B, hepatitis C and HIV before treatment as appropriate. [1]
- Consider continuing aciclovir or equivalent prophylaxis after bortezomib or another proteasome inhibitor ends. Also consider antiviral prophylaxis when an immunomodulatory drug and high-dose steroid are used together. [1]
- Teach patients to report new, changed or worsening neuropathy immediately. With bortezomib-associated symptoms, consider subcutaneous administration, weekly dosing or dose reduction; for another causative drug, consider reducing its dose. [1]
- Temporarily stop neuropathy-inducing treatment for grade 2 neuropathy with pain or grade 3–4 neuropathy. If it fails to improve and further treatment is required, consider a less neurotoxic alternative. [1]
Monitor longitudinally and reassess transplant options
- Monitor smouldering myeloma every 3 months for the first 5 years, then tailor frequency to stability. After treatment and recovery, monitor myeloma at least every 3 months, considering progression risk. [1]
- Monitoring includes symptoms, full blood count, renal function, bone profile, immunoglobulins and protein electrophoresis, with free light chains when appropriate. Do not use routine skeletal surveys; consider symptom-directed imaging for new bone symptoms. [1]
- After relapse and re-induction without progression, offer a suitable second autologous transplant when the first response lasted more than 24 months; consider it when that response lasted 12–24 months. [1]
- Provide access to a myeloma multidisciplinary team, supportive and palliative services, psychological support and an acute oncology or haematology helpline. Explain treatment toxicity, bone and renal health, and how to report new pain or possible cord-compression symptoms. [1]
Limitations and use
- The reviewed guideline was published in 2016 and updated in 2018. It explicitly complements separate technology appraisals, so its included drug examples are not a complete current first-line or relapse-treatment hierarchy. Only recommendations explicitly referring to smouldering myeloma apply to that condition. Spinal-cord compression and thrombosis management require their linked guidance.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Myeloma: diagnosis and management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 10 February 2016
- Publisher’s latest update
- 25 October 2018
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- United Kingdom
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.